WYWeili You

Weili You

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Weili You has a total of 3 co-authors. Here are the top co-authors by number of shared publications:

  • Fanjian Kong

    Department of Pharmacy Affiliated Lianyungang Hospital of Xuzhou Medical University/First People's Hospital of Lianyungang Lianyungang Jiangsu Province China

    1 shared publication
  • Jie Pang

    Department of Cardiovascular Medicine, Heart Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital) Hangzhou Medical College Hangzhou Zhejiang China

    1 shared publication
  • Ting Wang

    Department of pharmacy Zhangjiagang Hospital of Traditional Chinese Medicine Zhangjiagang Jiangsu Province China

    1 shared publication

Latest Publications

  • Identification and characterization of the in vitro metabolites of batatasin III by liquid chromatography in combination with Orbitrap mass spectrometry

    by Fanjian Kong, Ting Wang, Weili You

    Rationale: Batatasin III is a biologically active ingredient extracted from Dendrobium scabrilingue , which has been demonstrated to have anticancer activity. To fully understand its action, the present study was performed to investigate the in vitro metabolism of batatasin III using rat and human liver microsomes and hepatocytes. Methods: Batatasin III (20 μM) was incubated in the presence of NADPH‐supplemented rat and human liver microsomes (0.5 mg protein/mL) and hepatocytes (1 million cells/mL) followed by liquid chromatography in combination with hybrid quadrupole Orbitrap tandem mass spectrometric analysis to detect and identify the generated metabolites. The structures of the metabolites were characterized by comparing the accurate masses, elemental compositions as well as indicative fragment ions with those of the parent. Results: A total of 15 metabolites were detected and identified, including 4 phase I and 11 phase II metabolites. Batatasin III is subjected to bioactivation to form reactive quinoid intermediates, which subsequently react with glutathione (GSH) via Michael addition. Glucuronidation and GSH conjugation appear to be the primary elimination pathways in rat hepatocytes, while in human hepatocytes, GSH conjugates are formed to a lesser extent. Phase I metabolic pathways include hydroxylation and demethylation. Conclusions: The present study sheds light on the in vitro metabolic fates of batatasin III, which is indispensable for an understanding of its efficacy and safety.


  • Pharmacokinetics, bioavailability and metabolism of CC‐92480 in rat by liquid chromatography combined with electrospray ionization tandem mass spectrometry

    by Weili You, Jie Pang

    CC‐92480 is a cereblon E3 ubiquitin ligase modulating drug with potent antimyeloma activity. In this study, we developed a sensitive UHPLC–MS/MS method for the determination of CC‐92480 in rat plasma. The plasma samples were prepared with acetonitrile and the samples were then separated on an Acquity BEH C18 column (2.1 × 50 mm, 1.7 μm) with water containing 0.1% formic acid (A) and acetonitrile (B) as mobile phase. The MS detection was performed using multiple reaction monitoring mode with precursor‐to‐product ion transitions at m/z 568.3 > 363.1 for CC‐92480 and m/z 441.2 > 138.1 for ibrutinib (internal standard). The assay showed excellent linearity over the concentration range of 1–1,000 ng/ml, with correlation coefficient >0.995. The method was further validated for selectivity, precision, accuracy, recovery and stability according to the US Food and Drug Administration's guideline. The validated method was successfully applied to the pharmacokinetic and bioavailability studies of CC‐92480 in rat plasma. Based on the pharmacokinetic results, the oral bioavailability of CC‐92480 was >63%. In addition, the circulating metabolites of CC‐92480 were detected by UHPLC–HRMS and the structures were proposed according to their accurate masses and fragment ions. The proposed metabolic pathways of CC‐92480 were oxidative dealkylation and amide hydrolysis.